Skip to main content
IMJUDO 25 mg/1.25mL injection, solution by AstraZeneca Pharmaceuticals LP
IMJUDO, 25 mg/1.25mL, injection, solution Drug class: CTLA-4-directed Blocking Antibody. Available on prescription only. Listed by AstraZeneca Pharmaceuticals LP.
Prescription only

IMJUDO

tremelimumab

Listed by AstraZeneca Pharmaceuticals LP

Strength
25 mg/1.25mL
Form
Injection, Solution
Route
Intravenous
Class
CTLA-4-directed Blocking Antibody

What it contains

  • Tremelimumab 25 mg/1.25mL

FDA record

Dosage form Injection, Solution
Route Intravenous
Drug class CTLA-4-directed Blocking Antibody
Approval route BLA — biologic licence
NDC code 0310-4505
FDA application BLA761289
RxNorm concept 2619317
Package sizes listed 1
Marketed since October 2022

Other products containing Tremelimumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

IMJUDO

tremelimumab

Strength
300 mg/15mL
Form
Injection, Solution
Class
CTLA-4-directed Blocking Antibody
Rx only

AstraZeneca Pharmaceuticals LP

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.